- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01835665
Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations
May 12, 2016 updated by: University of California, San Francisco
An Open Label Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations
The purpose of this study is to determine the maximum tolerated dose of nimodipine as well as the safety and tolerability of oral nimodipine in progranulin mutation carriers in preparation for longer term efficacy studies in patients with frontotemporal dementia due to progranulin gene mutations.
Study Overview
Detailed Description
8 people with a GRN gene mutation will be given escalating doses of oral nimodipine for four weeks, followed by the maximally tolerated dose for four weeks.
To maximize enrollment, the trial will enroll both symptomatic and asymptomatic GRN mutation carriers.
The trial will include a four week, dose-escalation phase followed by 1-month maintenance phase, and a 1-week taper.
Assessments at the study site will take place prior to starting nimodipine, each week the dose is increased (weeks 1-5), after 4 weeks of maintenance dose, and 2 weeks after completion of the study.
These will include blood chemistry tests, ECGs, and blood pressure.
Both dose escalation and maintenance will focus on safety and tolerability of nimodipine treatment in this population as well as plasma progranulin levels as a biomarker outcome.
The trial will incorporate a variety of other fluid biomarker (blood and CSF) and imaging assessments to determine which will be most sensitive to nimodipine pharmacodynamic effects in this population.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- UCSF Memory and Aging Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria (all must be met):
- Signed and dated written informed consent obtained from the subject and/or the subject's caregiver in accordance with local IRB regulations
- Symptomatic GRN mutation carrier as defined by presence of known disease-associated GRN mutation confirmed by genetic testing and meeting international (2011) criteria for FTD (Rascovsky et al., 2011), Boeve (2003) criteria (B. F. Boeve, Lang, & Litvan, 2003) for CBS, or Gorno-Tempini criteria (2011) for primary progressive aphasia (Gorno-Tempini et al., 2011) (gene carrier status known) OR
- Asymptomatic GRN mutation carrier (gene carrier status known) from family with known disease-associated mutation;
- Age: >30
- MMSE ≥ 10 at screening visit.
- Judged by investigator to be able to comply with all study procedures
- In the opinion of the investigator, the patient will be compliant with the protocol and have a high probability of completing the study
- Lack of other recent, severe medical conditions.
Exclusion Criteria(Any one of the following will exclude a subject from being enrolled into the study):
- Hypersensitivity or other contra-indication to nimodipine use
- Systemic autoimmune disease (such as rheumatoid arthritis, thyroid disease, or diabetes) that might alter progranulin levels.
- Regular use of systemic corticosteroids or other anti-inflammatory medication. NSAID use acceptable if on a stable dose for 30 days prior to screening and agrees to remain on same dose for duration of trial.
- Subject is pregnant, plans to become pregnant during course of study or has a positive urine pregnancy test.
- Unwilling to use two forms of contraception if not surgically sterile for duration of study.
- History of cancer (other than basal cell CA of skin) within 5 years.
- History of myocardial infarction, cardiac conduction block, arrhythmia or other significant cardiac illness in the opinion of the investigator (in consultation with a board certified cardiologist).
- History of peptic ulcer.
- Metabolic disease such as gout or poorly controlled diabetes.
- History of alcohol or substance abuse within 1 year prior to screening, if deemed clinically significant by investigator.
- Any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.
- CT or MRI evidence of any of the following: hydrocephalus, stroke, space-occupying lesion, cerebral infection or any clinically significant CNS disease other than FTD, CBS, or progressive aphasia.
- Systolic blood pressure greater than 180 or less than 90 mm Hg. Diastolic blood pressure greater than 105 or less than 50 mm Hg.
- Abnormal ECG at screening and judged to be clinically significant by the investigator and/or board certified cardiologist.
- Use of investigational drugs or participation in investigational drug study within 30 days of screening or 5 half lives of the previous investigational drug, whichever is longer.
- Use of nimodipine within the 4 weeks prior to start of trial.
- Within 4 weeks of beginning or during the course of the study, concurrent treatment with calcium channel antagonists, blood thinners (e.g. clopidogrel, warfarin), or statin medication in combination with niacin.
- Clinically significant lab abnormalities at screening, including creatinine ≥ 1.7, B12 below laboratory normal reference range, or TSH above site's laboratory normal reference range. Subjects with abnormal B12 or TSH levels at screening may be included per investigator's discretion.
- Contraindication to MRI examination for any reason (e.g., severe claustrophobia, ferromagnetic metal in body).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nimodipine
|
Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum dose tolerated of nimodipine
Time Frame: up to 10 weeks
|
Nimodipine dose will be increased weekly for four weeks then maintained for 4 weeks at highest tolerated dose, followed by a 1-week taper.
|
up to 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma progranulin levels
Time Frame: up to 10 weeks post initial dosing
|
Plasma progranulin levels will be obtained at screening, baseline, and at each week dose is increased, after the 4 week maintenance phase, and 2 weeks after the taper.
Due to the small sample size, inferential statistics will not be calculated to assess the endpoints of interest.
However, descriptive statistics will be presented for the primary and secondary outcome measures (such as plasma and CSF progranulin levels) summarized by treatment group and visit.
For these continuous variables, the following information will be presented by visit: n, mean, standard deviation and order statistics (minimum, 25th percentile, median, 75th percentile and maximum).
These statistics will be presented using the actual value at baseline and the change from baseline for later data.
|
up to 10 weeks post initial dosing
|
Inflammatory marker levels (ESR, CRP, cytokines)
Time Frame: up to 10 weeks post initial dosing
|
Markers of inflammation will be obtained from the blood at screening, baseline, each week dose is increased, after 4 weeks of stable dose, and 2 weeks after the taper.
Due to the small sample size, inferential statistics will not be calculated to assess the endpoints of interest.
However, descriptive statistics will be presented for the primary and secondary outcome measures (such as plasma and CSF progranulin levels) summarized by treatment group and visit.
For these continuous variables, the following information will be presented by visit: n, mean, standard deviation and order statistics (minimum, 25th percentile, median, 75th percentile and maximum).
These statistics will be presented using the actual value at baseline and the change from baseline for later data.
|
up to 10 weeks post initial dosing
|
CSF progranulin
Time Frame: baseline (week 1) and 8 weeks after initial dosing
|
CSF progranulin levels will be obtained at baseline and week 8
|
baseline (week 1) and 8 weeks after initial dosing
|
CSF cytokines
Time Frame: baseline (week 1) and 8 weeks post dosing
|
CSF cytokines will be obtained at baseline and after 8 weeks of taking nimodipine
|
baseline (week 1) and 8 weeks post dosing
|
Brain MRI scan
Time Frame: Screening and week 8
|
To acquire preliminary data on the sensitivity of functional and brain MR imaging (resting-state functional connectivity and arterial spin label perfusion) to progranulin elevating therapies.
|
Screening and week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Adam Boxer, MD, PhD, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (Actual)
May 1, 2016
Study Completion (Actual)
May 1, 2016
Study Registration Dates
First Submitted
March 27, 2013
First Submitted That Met QC Criteria
April 16, 2013
First Posted (Estimate)
April 19, 2013
Study Record Updates
Last Update Posted (Estimate)
May 16, 2016
Last Update Submitted That Met QC Criteria
May 12, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHR12-09098
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
Data analysis is underway
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progranulin Mutation Carriers
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingScreening Breast MRI in Patients Who Are BRCA Mutation CarriersUnited States
-
University of GuelphMcMaster UniversityRecruitingAutosomal Recessive Disorder (Genetic Carriers of PKU)Canada
-
Tel-Aviv Sourasky Medical CenterEuropean UnionUnknownFocus of Study: Carriers of Resistant Enterobacteriaceae.Israel
-
University of GuelphMcMaster University; Laval UniversityNot yet recruitingAutosomal Recessive Disorder (Genetic Carriers of PKU)Canada
-
Lytix Biopharma ASCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMitochondrial Disorders | Li-Fraumeni Syndrome | Carriers of p53 MutationUnited States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo | Healthy Individuals With no Cardiopulmonary DiseaseUnited States
-
Pamela MunsterNational Cancer Institute (NCI)Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
-
Weill Medical College of Cornell UniversityBasser Research Center for BRCARecruiting
-
University of PennsylvaniaRecruiting
Clinical Trials on Nimodipine
-
Edge Therapeutics IncCompletedRuptured Cerebral Aneurysm | Ruptured Berry AneurysmUnited States, Canada, Czechia, Finland
-
Shenyang Dongxing Pharmaceutical Technology Co....Xuanwu Hospital, BeijingUnknownBioavailability | Safety Issues | Ischemic Cerebrovascular DiseaseChina
-
Edge Therapeutics IncTerminatedSubarachnoid Hemorrhage, AneurysmalUnited States, Canada, Australia, Hong Kong, Israel, New Zealand, Singapore, Finland, Czechia, Austria, Germany
-
University Hospital Hradec KraloveTerminatedMild Cognitive ImpairmentCzechia
-
Edge Therapeutics IncTerminatedSubarachnoid Hemorrhage, AneurysmalUnited States, Canada
-
Acasti Pharma Inc.CompletedAneurysmal Subarachnoid HemorrhageCanada
-
Second Affiliated Hospital, School of Medicine,...RecruitingSubarachnoid Hemorrhage, AneurysmalChina
-
Yuzhen PanDepartment of acupuncture and massage, Nanling Hospital of traditional Chinese...CompletedPost-stroke DementiaChina
-
B. Braun Medical International Trading Company...CompletedSubarachnoid HemorrhageChina
-
Medical University of ViennaRecruiting